Q3 PAT at Rs 49 cr, revenue up 11%; new ESOP 2026 covering 1.34 cr options approved
VIYASH · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.2 pts less than Nifty Microcap 250 and 2.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Board approved Q3 FY26 consolidated revenue at Rs 858.4 cr, up 10.9% YoY on restated basis. PAT rose to Rs 48.5 cr vs Rs 41.9 cr. Nine-month revenue stood at Rs 2,500.4 cr with PAT of Rs 158.3 cr. Q3 included exceptional amalgamation-related charges of Rs 41.3 cr (stamp duty, legal, banker fees). Also approved new ESOP 2026 covering up to 1.34 crore stock options (2.8 percent of post-merger capital), replacing the old VLSPL ESOP for existing grantees at 56-for-100 ratio. Three new SMPs appointed and one SMP role reclassified, all linked to post-amalgamation review.
Steady revenue growth and higher PAT are positive, but one-time merger costs and mild ESOP dilution (2.8 percent) may weigh on near-term optics.